Aeva Reports Second Quarter 2022 Results
Aeva (NYSE: AEVA) reported its Q2 2022 results, revealing a revenue of $1.5 million, a decline from $2.6 million in Q2 2021. The company experienced a GAAP operating loss of $35.7 million, up from $24.7 million a year prior. Cash and marketable securities stood at $378.9 million as of June 30, 2022. Aeva has successfully shipped its first Aeries II sensors and entered a strategic collaboration with SICK AG to expand its 4D LiDAR technology across industrial automation applications. CEO Soroush Salehian emphasized the company's commitment to meeting demand across multiple sectors.
- First Aeries II sensors shipped to strategic customers.
- Entered a multi-year collaboration with SICK AG for 4D LiDAR in industrial applications.
- Strong cash position with $378.9 million in cash and marketable securities.
- Revenue decreased from $2.6 million in Q2 2021 to $1.5 million in Q2 2022.
- GAAP operating loss increased to $35.7 million from $24.7 million year-over-year.
- GAAP net loss per share increased to $0.16 compared to $0.11 in Q2 2021.
Achieved key milestone with first Aeries II sensors shipped to strategic customers
Entered strategic collaboration with
Key Company Highlights
- Began shipping Aeries II™, the world’s first commercially available FMCW LiDAR-on-chip on the market, to strategic customers
-
Focused on scaling manufacturing to meet growing demand for
Aeva 4D perception technology from both existing and new engagements across multiple applications in automotive and non-automotive -
Solidified expansion in industrial automation, with a multi-year strategic collaboration with
SICK AG , to bring Aeva’s 4D LiDAR™ to a broad range of applications in high performance industrial sensing
“Aeva is progressing on track towards the next phase on our path to production,” said
Second Quarter 2022 Financial Highlights
-
Cash,
Cash Equivalents and Marketable Securities -
Cash, cash equivalents and marketable securities of
as of$378.9 million June 30, 2022
-
Cash, cash equivalents and marketable securities of
-
Revenue
-
Revenue of
in Q2 2022, compared to$1.5 million in Q2 2021$2.6 million
-
Revenue of
-
GAAP and Non-GAAP Operating Loss*
-
GAAP operating loss of
in Q2 2022, compared to GAAP operating loss of$35.7 million in Q2 2021$24.7 million -
Non-GAAP operating loss of
in Q2 2022, compared to non-GAAP operating loss of$29.3 million in Q2 2021$20.7 million
-
GAAP operating loss of
-
GAAP and Non-GAAP Net Loss per Share*
-
GAAP net loss per share of
in Q2 2022, compared to GAAP net loss per share of$0.16 in Q2 2021$0.11 -
Non-GAAP net loss per share of
in Q2 2022, compared to non-GAAP net loss per share of$0.13 in Q2 2021$0.10
-
GAAP net loss per share of
-
Shares Outstanding
- Weighted average shares outstanding of 216.9 million in Q2 2022
*Tables reconciling GAAP to non-GAAP measures are provided at the end of this release.
Conference Call Details
The company will host a conference call and live webcast to discuss results at
About
Aeva’s mission is to bring the next wave of perception to a broad range of applications from automated driving to industrial robotics, consumer electronics, consumer health, security and beyond.
Forward looking statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements in this press release include our beliefs regarding our financial position and operating performance for the second quarter of 2022 and business objectives for 2022, along with our expectations with respect to our orders, engagements and potential engagements with third parties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, but not limited to: (i) the ability to maintain the listing of Aeva’s securities on the
|
||||||||
Condensed Consolidated Balance Sheet |
||||||||
(Unaudited) |
||||||||
(In thousands) |
||||||||
|
|
|||||||
ASSETS |
||||||||
CURRENT ASSETS: |
||||||||
Cash and cash equivalents |
$ |
83,048 |
|
$ |
66,810 |
|
||
Marketable securities |
|
295,876 |
|
|
378,200 |
|
||
Accounts receivable, net |
|
353 |
|
|
2,341 |
|
||
Inventory |
|
1,854 |
|
|
2,063 |
|
||
Other current assets |
|
12,300 |
|
|
9,070 |
|
||
Total current assets |
|
393,431 |
|
|
458,484 |
|
||
Operating lease right-of-use assets |
|
8,862 |
|
|
10,284 |
|
||
Property and equipment, net |
|
8,520 |
|
|
5,136 |
|
||
Intangible assets, net |
|
3,975 |
|
|
4,425 |
|
||
Other assets |
|
860 |
|
|
859 |
|
||
TOTAL ASSETS |
$ |
415,648 |
|
$ |
479,188 |
|
||
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY |
||||||||
CURRENT LIABILITIES: |
||||||||
Accounts payable |
$ |
4,501 |
|
$ |
4,386 |
|
||
Accrued liabilities |
|
2,677 |
|
|
4,110 |
|
||
Accrued employee costs |
|
2,166 |
|
|
2,196 |
|
||
Lease liability, current portion |
|
2,925 |
|
|
2,872 |
|
||
Other current liabilities |
|
220 |
|
|
733 |
|
||
Total current liabilities |
|
12,489 |
|
|
14,297 |
|
||
Lease liability, noncurrent portion |
|
5,998 |
|
|
7,455 |
|
||
Warrant liability |
|
273 |
|
|
1,060 |
|
||
TOTAL LIABILITIES |
|
18,760 |
|
|
22,812 |
|
||
STOCKHOLDERS’ EQUITY: |
||||||||
Common stock |
|
22 |
|
|
21 |
|
||
Additional paid-in capital |
|
631,885 |
|
|
619,841 |
|
||
Accumulated other comprehensive loss |
|
(3,929 |
) |
|
(524 |
) |
||
Accumulated deficit |
|
(231,090 |
) |
|
(162,962 |
) |
||
TOTAL STOCKHOLDERS’ EQUITY |
|
396,888 |
|
|
456,376 |
|
||
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY |
$ |
415,648 |
|
$ |
479,188 |
|
|
||||||||||||||||
Condensed Consolidated Statements of Operations |
||||||||||||||||
(Unaudited) |
||||||||||||||||
(In thousands, except share and per share data) |
||||||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||||
Revenues: |
||||||||||||||||
Product |
$ |
466 |
|
$ |
241 |
|
$ |
677 |
|
$ |
534 |
|
||||
Professional service |
|
1,027 |
|
|
2,360 |
|
|
1,953 |
|
|
2,375 |
|
||||
Total revenues |
|
1,493 |
|
|
2,601 |
|
|
2,630 |
|
|
2,909 |
|
||||
Cost of revenues: |
||||||||||||||||
Product |
|
434 |
|
|
137 |
|
|
1,354 |
|
|
316 |
|
||||
Professional service (1) |
|
557 |
|
|
1,285 |
|
|
1,012 |
|
|
1,286 |
|
||||
Total cost of revenues |
|
991 |
|
|
1,422 |
|
|
2,366 |
|
|
1,602 |
|
||||
Gross profit (loss) |
|
502 |
|
|
1,179 |
|
|
264 |
|
|
1,307 |
|
||||
Research and development expenses (1) |
|
25,938 |
|
|
18,732 |
|
|
51,253 |
|
|
30,111 |
|
||||
General and administrative expenses (1) |
|
8,677 |
|
|
6,685 |
|
|
15,549 |
|
|
14,902 |
|
||||
Selling and marketing expenses (1) |
|
1,572 |
|
|
498 |
|
|
3,220 |
|
|
1,157 |
|
||||
Total operating expenses |
|
36,187 |
|
|
25,915 |
|
|
70,022 |
|
|
46,170 |
|
||||
Operating loss |
|
(35,685 |
) |
|
(24,736 |
) |
|
(69,758 |
) |
|
(44,863 |
) |
||||
Interest income |
|
586 |
|
|
106 |
|
|
869 |
|
|
109 |
|
||||
Other income, net |
|
128 |
|
|
557 |
|
|
761 |
|
|
1,223 |
|
||||
Net loss before taxes |
|
(34,971 |
) |
|
(24,073 |
) |
|
(68,128 |
) |
|
(43,531 |
) |
||||
Income tax provision |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
||||
Net loss |
$ |
(34,971 |
) |
$ |
(24,073 |
) |
$ |
(68,128 |
) |
$ |
(43,531 |
) |
||||
Net loss per share, basic and diluted |
$ |
(0.16 |
) |
$ |
(0.11 |
) |
$ |
(0.31 |
) |
$ |
(0.23 |
) |
||||
Shares used in computing net loss per share, basic and diluted |
|
216,886,078 |
|
|
211,551,522 |
|
|
216,454,032 |
|
|
188,024,155 |
|
||||
(1) Includes stock-based compensation as follows: |
||||||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||||
Cost of revenues |
$ |
206 |
|
$ |
410 |
|
$ |
342 |
|
$ |
410 |
|
||||
Research and development expenses |
|
4,652 |
|
|
2,022 |
|
|
8,975 |
|
|
3,818 |
|
||||
General and administrative expenses |
|
1,275 |
|
|
1,496 |
|
|
2,504 |
|
|
4,192 |
|
||||
Selling and marketing expenses |
|
301 |
|
|
81 |
|
|
397 |
|
|
102 |
|
||||
Total stock-based compensation expense |
$ |
6,434 |
|
$ |
4,009 |
|
$ |
12,218 |
|
$ |
8,522 |
|
|
||||||||
Statements of Cash Flows |
||||||||
(Unaudited) |
||||||||
(In thousands) |
||||||||
Six Months Ended |
||||||||
2022 |
2021 |
|||||||
Cash flows from operating activities: |
||||||||
Net loss |
$ |
(68,128 |
) |
$ |
(43,531 |
) |
||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
Depreciation and amortization |
|
1,429 |
|
|
469 |
|
||
Change in fair value of warrant liability |
|
(787 |
) |
|
(1,240 |
) |
||
Stock-based compensation |
|
12,218 |
|
|
8,522 |
|
||
Impairment of inventories |
|
842 |
|
|
— |
|
||
Amortization of right-of-use assets |
|
1,422 |
|
|
582 |
|
||
Realized loss on investment |
|
29 |
|
|
— |
|
||
Amortization of premium on available-for-sale securities |
|
636 |
|
|
416 |
|
||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
|
1,988 |
|
|
(1,397 |
) |
||
Inventories |
|
(296 |
) |
|
(528 |
) |
||
Other current assets |
|
(3,230 |
) |
|
(5,028 |
) |
||
Other noncurrent assets |
|
(1 |
) |
|
(296 |
) |
||
Accounts payable |
|
(359 |
) |
|
1,905 |
|
||
Accrued liabilities |
|
(1,788 |
) |
|
6,332 |
|
||
Accrued employee costs |
|
(30 |
) |
|
182 |
|
||
Lease liability |
|
(1,404 |
) |
|
(414 |
) |
||
Other current liabilities |
|
(512 |
) |
|
34 |
|
||
Net cash used in operating activities |
|
(57,971 |
) |
|
(33,992 |
) |
||
Cash flows from investing activities: |
||||||||
Purchase of property, plant and equipment |
|
(3,872 |
) |
|
(1,202 |
) |
||
Purchase of available-for-sale securities |
|
(139,714 |
) |
|
(366,204 |
) |
||
Proceeds from maturities of marketable securities |
|
217,968 |
|
|
20,123 |
|
||
Net cash provided by (used in) investing activities |
|
74,382 |
|
|
(347,283 |
) |
||
Cash flows from financing activities: |
||||||||
Proceeds from business combination and private offering |
|
— |
|
|
560,777 |
|
||
Transaction costs related to business combination and private offering |
|
— |
|
|
(47,487 |
) |
||
Payments of taxes withheld on net settled vesting of restricted stock units |
|
(418 |
) |
|
— |
|
||
Proceeds from exercise of warrants |
|
1 |
|
|
— |
|
||
Proceeds from exercise of stock options |
|
244 |
|
|
360 |
|
||
Net cash provided by financing activities |
|
(173 |
) |
|
513,650 |
|
||
Net increase (decrease) in cash and cash equivalents |
|
16,238 |
|
|
132,375 |
|
||
Beginning cash and cash equivalents |
|
66,810 |
|
|
24,624 |
|
||
Ending cash and cash equivalents |
$ |
83,048 |
|
$ |
156,999 |
|
|
||||||||||||||||
Reconciliation of GAAP to Non-GAAP Operating Results |
||||||||||||||||
(Unaudited) |
||||||||||||||||
(In thousands, except share and per share data) |
||||||||||||||||
Reconciliation from GAAP to non-GAAP operating loss |
||||||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||||
GAAP operating loss |
|
$ |
(35,685 |
) |
|
$ |
(24,736 |
) |
|
$ |
(69,758 |
) |
|
$ |
(44,863 |
) |
Stock-based compensation |
|
|
6,434 |
|
|
|
4,009 |
|
|
12,218 |
|
|
|
8,522 |
|
|
Non-GAAP operating loss |
|
$ |
(29,251 |
) |
|
$ |
(20,727 |
) |
|
$ |
(57,540 |
) |
|
$ |
(36,341 |
) |
Reconciliation from GAAP to non-GAAP net loss |
||||||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||||
|
||||||||||||||||
GAAP net loss |
|
$ |
(34,971 |
) |
|
$ |
(24,073 |
) |
|
$ |
(68,128 |
) |
|
$ |
(43,531 |
) |
Stock-based compensation |
|
|
6,434 |
|
|
|
4,009 |
|
|
12,218 |
|
|
|
8,522 |
|
|
Change in fair value of warrant liability |
|
|
(153 |
) |
|
|
(572 |
) |
|
|
(787 |
) |
|
|
(1,240 |
) |
Non-GAAP net loss |
$ |
(28,690 |
) |
$ |
(20,636 |
) |
$ |
(56,697 |
) |
$ |
(36,249 |
) |
||||
Reconciliation between GAAP and non-GAAP net loss per share |
||||||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||||||
Shares used in computing GAAP net loss per share: |
|
|
|
|
|
|
|
|
||||||||
Basic and diluted |
|
216,886,078 |
|
|
211,551,522 |
|
|
216,454,032 |
|
|
188,024,155 |
|
||||
GAAP net loss per share |
|
|
|
|
|
|
|
|
||||||||
Basic and diluted |
$ |
(0.16 |
) |
$ |
(0.11 |
) |
$ |
(0.31 |
) |
$ |
(0.23 |
) |
||||
Stock-based compensation |
|
|
0.03 |
|
|
|
0.01 |
|
|
|
0.05 |
|
|
|
0.05 |
|
Warrant liability |
|
(0.00 |
) |
|
(0.00 |
) |
|
(0.00 |
) |
|
(0.01 |
) |
||||
Non-GAAP net loss per share |
|
|
|
|
|
|
|
|
||||||||
Basic and diluted |
$ |
(0.13 |
) |
$ |
(0.10 |
) |
$ |
(0.26 |
) |
$ |
(0.19 |
) |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005891/en/
Investors:
investors@aeva.ai
Media:
press@aeva.ai
Source:
FAQ
What were Aeva's Q2 2022 revenue results?
How did Aeva's operating loss change in Q2 2022?
What is the current cash position of Aeva?
What strategic collaboration did Aeva enter in Q2 2022?